1. Home
  2. DOCU vs GKOS Comparison

DOCU vs GKOS Comparison

Compare DOCU & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DocuSign Inc.

DOCU

DocuSign Inc.

N/A

Current Price

$71.76

Market Cap

10.2B

Sector

Technology

ML Signal

N/A

Logo Glaukos Corporation

GKOS

Glaukos Corporation

N/A

Current Price

$168.70

Market Cap

10.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DOCU
GKOS
Founded
2003
1998
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Medical/Dental Instruments
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.2B
10.6B
IPO Year
2018
2015

Fundamental Metrics

Financial Performance
Metric
DOCU
GKOS
Price
$71.76
$168.70
Analyst Decision
Hold
Strong Buy
Analyst Count
17
12
Target Price
$63.33
$126.92
AVG Volume (30 Days)
3.2M
573.4K
Earning Date
06-04-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.80
N/A
Revenue
$3,219,500,000.00
$507,442,000.00
Revenue This Year
$10.58
$23.32
Revenue Next Year
$7.33
$27.43
P/E Ratio
$89.81
N/A
Revenue Growth
8.16
32.33
52 Week Low
$40.16
$73.16
52 Week High
$86.65
$191.62

Technical Indicators

Market Signals
Indicator
DOCU
GKOS
Relative Strength Index (RSI) 69.34 45.52
Support Level $42.89 $96.44
Resistance Level N/A $184.68
Average True Range (ATR) 2.78 6.22
MACD 0.25 -2.25
Stochastic Oscillator 85.56 31.38

Price Performance

Historical Comparison
DOCU
GKOS

About DOCU DocuSign Inc.

Docusign offers Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its initial public offering in 2018.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: